Emerging Data and Future Directions in UC

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS

FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Ariana Pelosci

March 28th 2025

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Matthew Fowler;Jun Gong, MD

March 15th 2022

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

March 11th 2025

Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

sBLAs Submitted for Nogapendekin Alfa Inbakicept in Lymphopenia/NMIBC

Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.

Related Content

Roman Fabbricatore

April 16th 2025

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS

FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Ariana Pelosci

March 28th 2025

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

Matthew Fowler;Jun Gong, MD

March 15th 2022

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

March 11th 2025

Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.